Literature DB >> 3491886

Test-retest studies of cerebral glucose metabolism using fluorine-18 deoxyglucose: validation of method.

R A Brooks, G Di Chiro, B W Zukerberg, D Bairamian, S M Larson.   

Abstract

In studies using [18F]deoxyglucose (FDG), one often wants to compare metabolic rates following stimulation (drug or motor-sensory) with the baseline values. However, because of reproducibility problems with baseline variations of 25% in the same individual not uncommon, the global effect of the stimulation may be difficult to see. One approach to this problem is to perform the two studies sequentially. This means that, with the 110-min half-life of 18 F, one must take into account the residual activity from the first study when calculating metabolic rates for the second. We performed TEST-RETEST baseline studies on four subjects, with a 1-hr interval between injections. These studies were done without stimulation, in order to validate the repeatability of the method. To reduce the amount of residual activity from the first study, the first injection was only 2 mCi in three cases, and only 1 mCi in one case, out of a total injected dose of 5 mCi. A correction for residual activity was included in the RETEST calculation of metabolic rate. The results showed a global metabolic shift between the two studies of 2% to 9%. An error analysis shows that the shift could be further reduced if anatomically comparable scans are done at comparable postinjection times.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3491886

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  Six-month test-retest reliability of MRI-defined PET measures of regional cerebral glucose metabolic rate in selected subcortical structures.

Authors:  S M Schaefer; H C Abercrombie; K A Lindgren; C L Larson; R T Ward; T R Oakes; J E Holden; S B Perlman; P A Turski; R J Davidson
Journal:  Hum Brain Mapp       Date:  2000-05       Impact factor: 5.038

2.  Changes in glucose uptake by malignant gliomas: preliminary study of prognostic significance.

Authors:  J M Rozental; R L Levine; R J Nickles
Journal:  J Neurooncol       Date:  1991-02       Impact factor: 4.130

3.  Effects of m-chlorophenylpiperazine on regional brain glucose utilization: a positron emission tomographic comparison of alcoholic and control subjects.

Authors:  D Hommer; P Andreasen; D Rio; W Williams; U Ruttimann; R Momenan; A Zametkin; R Rawlings; M Linnoila
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

4.  Reproducibility of cerebral glucose utilization measured by PET and the [18F]-2-fluoro-2-deoxy-d-glucose method in resting, healthy human subjects.

Authors:  P Maquet; D Dive; E Salmon; R von Frenckel; G Franck
Journal:  Eur J Nucl Med       Date:  1990

5.  Binding of the synaptic vesicle radiotracer [11C]UCB-J is unchanged during functional brain activation using a visual stimulation task.

Authors:  Kelly Smart; Heather Liu; David Matuskey; Ming-Kai Chen; Kristen Torres; Nabeel Nabulsi; David Labaree; Jim Ropchan; Ansel T Hillmer; Yiyun Huang; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2020-08-05       Impact factor: 6.200

6.  Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme.

Authors:  J M Rozental; J D Cohen; M P Mehta; R L Levine; J M Hanson; R J Nickles
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

7.  Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography.

Authors:  G Wik; F A Wiesel; I Sjögren; G Blomqvist; T Greitz; S Stone-Elander
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Simultaneous determination of dynamic cardiac metabolism and function using PET/MRI.

Authors:  Gregory P Barton; Lauren Vildberg; Kara Goss; Niti Aggarwal; Marlowe Eldridge; Alan B McMillan
Journal:  J Nucl Cardiol       Date:  2018-05-01       Impact factor: 5.952

9.  Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study.

Authors:  Ming-Kai Chen; Adam P Mecca; Mika Naganawa; Jean-Dominique Gallezot; Takuya Toyonaga; Jayanta Mondal; Sjoerd J Finnema; Shu-Fei Lin; Ryan S O'Dell; Julia W McDonald; Hannah R Michalak; Brent Vander Wyk; Nabeel B Nabulsi; Yiyun Huang; Amy Ft Arnsten; Christopher H van Dyck; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2021-03-24       Impact factor: 6.200

10.  Towards quantitative [18F]FDG-PET/MRI of the brain: Automated MR-driven calculation of an image-derived input function for the non-invasive determination of cerebral glucose metabolic rates.

Authors:  Lalith Ks Sundar; Otto Muzik; Lucas Rischka; Andreas Hahn; Ivo Rausch; Rupert Lanzenberger; Marius Hienert; Eva-Maria Klebermass; Frank-Günther Füchsel; Marcus Hacker; Magdalena Pilz; Ekaterina Pataraia; Tatjana Traub-Weidinger; Thomas Beyer
Journal:  J Cereb Blood Flow Metab       Date:  2018-05-23       Impact factor: 6.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.